Cigarette smoking and serum soluble Fas levels: Findings from the JACC study.
ABSTRACT Cigarette smoking enhances low-grade systemic inflammation in the lung and other organs. Activated immune cells play an important role at early and late stages of inflammation, and in recent years, soluble Fas (sFas), an isoform of death molecule Fas, was found to interfere with the apoptotic pathways of these activated immune cells. The aim of this study was to confirm the association between cigarette smoking and sFas levels in healthy male subjects. We measured serum sFas levels of 4415 male subjects selected as controls for a nested case-control study within the large-scale cohort study conducted in Japan, called the JACC Study. Smoking status at baseline was evaluated by a self-administered questionnaire. Least square means of sFas according to smoking status and numbers of cigarettes smoked per day among smokers were calculated and adjusted for possible confounding factors. Mean sFas levels showed an increasing trend across never smokers, past smokers and current smokers, as 2.21 (95% CI: 2.14-2.27) ng/ml, 2.29 (2.22-2.36) ng/ml, and 2.36 (2.30-2.43) ng/ml, respectively. However, no dose-response relationship was observed between the number of cigarettes smoked per day and sFas levels among smokers.
Article: Profile of the JACC study.[show abstract] [hide abstract]
ABSTRACT: A large-scale population-based cohort study would offer the best evidence of a relation between lifestyle and cancer. The Japan Collaborative Cohort Study (JACC Study) for Evaluation of Cancer Risk sponsored by the Ministry of Education, Science, Sports and Culture of Japan (Monbusho) was established and carried out from 1988 to 1990 in 45 areas in Japan. Epidemiological information, such as demographic information, past medical history, exercise/sports activities engaged in, frequency of food intake, smoking and alcohol drinking status and so on, was collected by a self-administered questionnaire. Blood samples were collected from each participant at screening in 37 out of 45 areas to investigate risk factors of cancer relating to biochemical substances in blood. Collected sera were divided into 3-5 tubes (100-500 microL per tube) and stored at -80 degrees C. Additionally, about 5 years after the baseline survey, an interim survey regarding lifestyle changes was conducted in 31 areas. We followed the study subjects for mortality, move-outs, and cancer incidence, if possible (in 24 areas). There were 127,477 participants (54,032 men and 73,445 women) registered in the study. Of these, 110,792 subjects (46,465 men and 64,327 women), aged 40 to 79 years at baseline, were eligible for follow-up. Sera were stocked from 39,242 subjects, and interim survey was carried out on 46,650 subjects. The JACC Study provides useful evidence for cancer prevention in Japan.Journal of Epidemiology 04/2005; 15 Suppl 1:S4-8. · 2.11 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: The aims of the present study are to evaluate the difference of the levels of soluble Fas (sFas) antigen between patients with systemic lupus erythematosus (SLE) and healthy controls and to explore whether sFas has a role in either the disease activity or the organ damage in SLE. Serum levels of sFas were measured in 40 Chinese patients with SLE and 15 age-, gender-, and race-matched healthy controls using double antibody ELISA. SLEDAI scores for disease activity were determined. Data of organ and tissue damage was obtained from clinical records. Serum sFas levels were significantly increased in both more active (mean=8043.8 pg/ml, P<0.001) and less active SLE patients (mean=4820.2 pg/ml, P<0.001) comparing to the healthy controls (mean=3253.4 pg/ml). There was also a significant difference in serum sFas levels between the more active SLE patients and less active SLE patients (P=0.04). But, the levels of sFas didn't correlate with SLEDAI. There was a significant difference in the serum sFas levels between patients with and without CNS disease (mean=9582.6, 6634.5 pg/ml; P=0.007). The same was true when patients with and without renal disease (mean=10972.7, 6520.1 pg/ml; P=0.019), as well as serositis (mean=10385.3, 6709.1 pg/ml; P=0.005) were analyzed. sFas is elevated in sera of SLE patients, especially in patients with active SLE. The elevated levels of sFas in the sera of patients with SLE may be closely associated with damage to the kidneys, central nervous system and serosa. Serum sFas may serve as a predictor of some organ and tissue damage in SLE.Archives for Dermatological Research 01/2006; 297(7):329-32. · 2.71 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Measurement of IL-6 has been widely undertaken to examine inflammatory and immune responses to exercise. Use of salivary IL-6 offers an alternative to the invasive collection procedures required for IL-6 measurement in plasma samples. Rarely, however, has the degree of association between plasma and salivary IL-6 been reported. The aim of the current study was to investigate the relationship between resting salivary and plasma IL-6 concentrations in 45 trained distance runners (36 males, 9 females; age: 35.1 +/- 8.0 y, mean +/- SD). Plasma and saliva samples were collected from athletes under resting conditions. Plasma IL-6 concentrations were determined using a Bioplex suspension array system and commercially available reagents. Salivary IL-6 concentrations were determined using a commercially available high-sensitivity ELISA kit. At rest, the mean (+/- SD) plasma IL-6 concentration was 3.43 +/- 3.75 pg mL(-1) compared to a mean salivary IL-6 concentration of 1.80 +/- 4.25 pg mL(-1). IL-6 concentrations in plasma and saliva samples were not correlated (r = -0.031, p = 0.85). At rest, salivary IL-6 concentrations do not reflect plasma IL-6 concentrations. The potential for salivary IL-6 to act as a surrogate marker for plasma IL-6 responses when examining inflammatory and immune responses to exercise, therefore, appears unlikely.Arbeitsphysiologie 04/2008; 103(4):477-9. · 2.66 Impact Factor